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ABSTRACT 
Hepatitis B virus (HBV) is one of the major causes of 
chronic hepatitis, cirrhosis and liver cancer. In com-
bating HBV infections, HBV diagnosis and vaccina-
tion are therefore critical. The hepatitis B virus sur-
face antigen (HBsAg) is a key target molecule in de-
veloping vaccines and diagnostic systems. To date, al- 
though HBsAg has been expressed in bacteria, yeasts 
and mammalian cells, there are still limitations in the 
existing ones, which leave the necessity for searching 
new HBsAg production methods. In this study, a sim-
ple phage display-based method was developed to 
produce the purified full-length HBsAg molecules for 
further immunization studies. For this purpose, the 
HBsAg coding gene was cloned into a pCANTAB5E 
phagemid vector and expressed on the surface of M13 
filamentous phages. The HBsAg-expressing phage na- 
nosystem was then used as immunization agent in 
BALB/cJ mice. The ELISA results for sera obtained 
from mice immunized with HBsAg-displaying phage 
particles revealed an immune response against 
HBsAg. These results demonstrate the potential use 
of a full-length antigen to be displayed on phages as 
cost effective adjuvant-free immunization agents as 
an alternative to the highly purified and more expen-
sive antigens conjugated with carrier molecules.  
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1. INTRODUCTION 
Hepatitis B virus (HBV) is one of the major causes of 
chronic hepatitis, cirrhosis and liver cancer [1]. Accord-
ing to the World Health Organization (WHO), the num-
ber of infected people in 2009 was greater than 2 billion, 
350 million of whom were HBV carriers. Every year, 
approximately 500,000 to 700,000 people die from HBV- 
related diseases. Although the incidence of HBV infec-
tion has decreased in developed countries due to the im-
plementation of vaccination programs [2], HBV still re-
mains an important health problem in developing coun-
tries.  
HBV belongs to the Hepadnaviridae virus family, 
which infects human hepatocytes. HBV infection results 
in the release of infectious virions and excessive hepatitis 
B surface antigens (HBsAg) from host cells to the blood-
stream. Therefore, the presence of HBsAg in circulating 
blood is an indicator of HBV infection. ELISA kits are 
widely used throughout the world to detect HBsAg and 
anti-HBsAg antibodies, and thus, HBsAg production is 
important for the manufacture of ELISA-based HBV 
diagnostic kits. However, the primary need for HBsAg 
production is to develop vaccines against HBV. Thus, the 
development of a cost-effective method of producing 
HBsAg for vaccine advancement is of great importance. 
HBsAg was first purified from human plasma in 1980 
[3]. It was then produced in a recombinant yeast system 
[4], followed by expression in mammalian cells [5]. 
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However, the production and purification processes for 
HBsAg are expensive and time consuming. Several years 
ago, a lower-cost method using phage display for the 
expression of HBsAg for immunization purposes was 
demonstrated [6]. Tan et al. fused the 111 - 156 amino 
acid-coding DNA region of HBsAg, including the domi-
nant neutralizing epitope “a”, with T7 phage capsid pro-
teins. T7 phages expressing the 45 amino acid-length 
partial HBsAg on their surfaces were used as immuniza-
tion agents in rabbits.  
Phage display is a powerful technology in which fu-
sion proteins are displayed on phage surfaces using coat 
proteins [7-9]. This technology has been widely used for 
the selection of recombinant antibodies, such as Fab, sin- 
gle chain variable fragments or peptides that are able to 
bind various target molecules such as growth factor re-
ceptors, growth factors, viral antigens and even inorganic 
materials for diagnosis, tumor targeting and drug discov-
ery [10-14]. Phage display has recently been used in new 
applications for vaccine development by displaying pep-
tides derived from virus antigens on the phage surface 
[15-17]. Until now, the full-length HBsAg has not been 
displayed on the phage surface for use in immunization 
applications. 
Here, we describe the expression of the entire small 
HBsAg on phage surfaces as a pIII fusion protein. We 
further use these recombinant phage nanoparticles as im- 
munization agents in immunocompetant BALB/cJ mouse 
strain.  
2. MATERIAL AND METHODS 
2.1. Materials 
The plasmid construct containing the HBsAg coding 
gene was kindly provided by Assoc. Prof. Mehmet Yapar 
of the Virology Department from Gulhane Military Me- 
dical Faculty, Gulhane Military Medical Faculty (GATA) 
[18]. Escherichia coli strain TG1 (Δ(lac-pro), supE, thi, 
hsdD5/Fʹ,traD36, proAB, LacIq, lac ZΔM15) was used 
as a bacterial host. The phagemid vector pCANTAB5E 
(Pharmacia, Stockholm, Sweden) was used for the phage 
display (Figure 1). BALB/cJ mice were obtained from 
the Animal Genetics and Reproduction Biology Labora-
tory of the TUBITAK Marmara Research Center, Genetic 
Engineering and Biotechnology Institute, Turkey. Animal 
studies were approved by the Ethics Committee of the 
Genetic Engineering and Biotechnology Institute, TU-
BITAK Marmara Research Center. 
2.2. HBsAg-Encoding Gene Cloning into a  
Phagemid Vector  
The HBsAg-encoding gene was amplified by PCR using 
a sense strand primer (5’-ACTCGCGGCCCAGCCGGC  
 
Figure 1. Map of pCANTAB5E phagemid vector. “The Re-
combinant Phage Antibody System (RPAS) Expression Mod-
ule/Recombinant Phage Antibody System protocol handbook 
(Pharmacia, Stockholm, Sweden). 
 
CATGGAGAACATCACATCAGG-3’) including a SfiI 
restriction site (underlined) and an anti-sense strand pri-
mer (5’-CATTCTGCGGCCGCTTTGTTTTGTTAGGGT 
TTAA-3’) including a NotI restriction site (underlined). 
The PCR reaction was performed as follows: 1 min at 
94˚C, 2 min at 55˚C and 2 min at 72˚C for a total of 30 
cycles. The PCR-amplified fragment and the pCAN-
TAB5E vector were first digested with SfiI and then with 
NotI. Agarose gel-purified SfiI/NotI digestion products 
were ligated to each other and then transformed into E. 
coli TG1 (Amersham Pharmacia Biotech, Buckingham-
shire, England) by calcium chloride transformation [19]. 
The transformed cells were heated at 95˚C for 5 min to 
release the plasmids into the medium. The HBsAg gene 
insert in the plasmids was controlled by colony PCR us-
ing a heat-treated bacterial suspension as a template. 
Plasmids from the positive clones were purified and then 
sequenced with the GenomeLab DTCS Quick Start Kit 
(Beckman Coulter, Brea, USA) using a forward primer 
(TATGACCATGATTACGCCAAG) and a reverse primer 
(TTTTGTCGTCTTTCCAGACGTT). The raw sequenc-
ing data were analyzed using a CEQ 8800 Genetic Anal-
ysis System (Beckmann Coulter), and the DNA se-
quences were then uploaded to the SDCD Biology 
Workbench Internet website (http://workbench.sdsc.edu), 
where multiple alignments, database searches and protein 
translations were conducted. 
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2.3. HBsAg Expression on the Phage Surface 
A single positive transformed colony was selected and 
grown overnight at 37˚C in 2XTY medium (10 g Bacto- 
Tryptone, 5 g yeast extract and 10 g NaCl per liter) con-
taining 100 μg/ml ampicillin and 2% glucose for phage 
rescue. The next day, the overnight culture was inocu-
lated into fresh medium containing 100 μg/ml ampicillin 
and 2% glucose. When the absorbance at 600 nm reached 
0.5, 1010 pfu of M13KO7 helper phage (New England 
Biolabs, Beverly, MA) were added to the culture and 
incubated for 45 min at 37˚C without shaking and 45 min 
at 37˚C with shaking. The culture was centrifuged, and 
the cells were resuspended in 2XTY medium containing 
100 μg/ml ampicillin and 50 μg/ml kanamycin. The cul-
ture was incubated overnight at 30˚C with shaking. The 
next day, phage particles were precipitated using polye-
thylene glycol-6000 (1 M PEG 6000 and 2.5 M NaCl) 
and then centrifuged for 40 min at 25000 × g. The phage 
particle pellet was resuspended in 1 ml of phosphate- 
buffered saline (PBS; 3.2 mM Na2HPO4 × 2H2O, 1.4 
mM KH2PO4, 2.7 mM KCl and 137 mM NaCl) and then 
filter sterilized using a 0.45-μm Millex-HV membrane 
(Millipore, Billerica, MA). 
2.4. ELISA for HBsAg-Displaying Phage  
Particles 
Two different ELISA methods have been used to detect 
the HBsAg displayed on phage particles. Each assay was 
conducted in triplicate.  
2.4.1. First ELISA Method 
Phage particles that did (recombinant phage) or did not 
(wild-type phage) display HBsAg were used to coat each 
ELISA plate well at 1010 phage particles per well over-
night. The next day, the wells were washed with TPBS 
(PBS with 0.1% Tween-20) and then blocked with TPBS 
containing 1% BSA. Polyclonal rabbit anti-HBsAg anti-
body (1/200) was used as a primary antibody, and goat 
anti-rabbit alkaline phosphatase (Thermo Scientific, 
Rockford, Illinois, USA) conjugate (1/1000) was used as 
a secondary antibody. A para-nitrophenylphosphate sub-
strate solution was used as a chromogen. The absorbance 
was measured at 405 nm using an ELISA reader (Bio- 
Rad). 
2.4.2. Second ELISA Method 
ELISA plate wells were coated overnight with rabbit 
anti-HBsAg polyclonal antibody (1/200). The next day, 
the wells were washed with TPBS (PBS with 0.1% 
Tween-20) and then blocked with TPBS containing 1% 
BSA. Phage particles (1010) displaying HBsAg or wild- 
type phage were then added to each well. Mouseanti- 
M13 horseradish peroxidase (GE Healthcare, Freiburg, 
Germany) conjugate (1/1000) was used as a secondary 
antibody. The absorbance was measured at 410 nm using 
an ELISA reader (Bio-Rad) after the addition of a 2,2’- 
azino-bis (3-ethylbenzothiazoline-6-sulphonic acid (ABTS) 
substrate solution. 
2.5. Mouse Immunization Assay 
Immunization assays were conducted with 8-week-old 
male immunocompetant BALB/cJ mice. Six different 
mice groups containing 3 mice each were subjected to 
different injections without any adjuvant. The first 3 
groups received 300 μl of solutions with different con-
centrations of phage displaying HBsAg (1010, 1011 and 
1012 phage particles diluted in PBS). The fourth and fifth 
groups received 1011 or 1012 phage particles without 
HBsAg in 300 μl of PBS. The mice in group 6 received 
300 μl of PBS as a control. All immunizations were per-
formed in triplicate at 3-week intervals. Intradermal in-
jections were conducted using 50 μl under each front leg 
and 100 μl under each back leg pit. Blood samples were 
collected from the tail of each mouse before each injec-
tion; the last bleed was performed 4 d after the last injec-
tion. Blood samples were centrifuged, and the superna-
tants were stored for ELISA assays.  
2.6. ELISA of Mice Blood after Immunization 
ELISA plate wells were coated overnight with 200 ng of 
HBsAg (Ad/Ay, 100 ng each) (Fitzgerald Industries In-
ternational, North Acton, MA, USA). The next day, the 
wells were washed with TPBS (PBS with 0.1% Tween- 
20) and then blocked with TPBS containing 1% BSA. 
The mice sera (1/50) were then incubated for 1 h at room 
temperature. The wells were washed with TPBS, and goat 
anti-mouse HRP conjugate (Thermo Scientific, Rockford, 
Illinois, USA) was added (1/1000) and incubated for 1 h. 
After the addition of ABTS substrate solution, the ab-
sorbance was measured at 410 nm with an ELISA reader 
(Bio-Rad). 
2.7. Statistical Analysis 
The IBM SPSS Statistics (SPSS), version 17 for Win-
dows was used for statistical analysis. The differences in 
BALB/cJ mice humoral immune response between 
groups were analyzed using mixed model ANOVA with 
Tukey post hoc test. The significant difference between 
groups and within groups at different injection periods 
were analyzed using univariate General Linear Model 
with Tukey post hoc test. p values of <0.05 were consi-
dered statistically significant. 
3. RESULTS  
3.1. Construction of HBsAg-Displaying Phages 
The HBsAg gene provided by GATA [18] was amplified 
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by polymerase chain reaction (PCR), and the product 
was run on a 1.2% agarose gel. A single ~700 bp band 
was observed as expected (data not shown). The PCR 
product was then cloned into the pCANTAB5E phage-
mid vector. The recombinant phagemid vector was then 
transferred into TG1 E. coli cells. Twenty randomly se-
lected transformed cells were used for colony PCR. 
Three colonies identified as positive PCR product clones 
were selected and prepared for dye-terminated DNA se-
quence analysis. The resulting sequences were translated 
using the San Diego Supercomputer Center (SDSC) Bi-
ology Workbench Internet website. The protein se-
quences resulting from translation were compared with 
HBsAg and pIII protein sequences by CLUSTALW mul-
tiple sequence alignment. Sequencing showed that 
HBsAg was properly cloned into the phagemid vector 
and fused to pIII without any frame shift.  
3.2. Phage ELISA 
Phages displaying HBsAg were collected by phage res-
cue using an M13 helper phage. The titer of the phage 
particles purified by PEG precipitations was estimated. A 
phage concentration of approximately 4 × 1012 phage 
particles/ml was obtained after each phage rescue step. 
Two different ELISA methods were used to verify the 
HBsAg display on the phage particles (Figure 2). In the 
first method, ELISA plate wells were coated either with 
phage particles displaying HBsAg or wild-type phages. 
Then, a rabbit anti-HBsAg polyclonal antibody was used 
as a primary antibody, and goat anti-rabbit AP conjugate 
was used as the secondary antibody. The ELISA results 
had a 9-fold higher binding signal for HBsAg-displaying 
phages relative to the wild-type phages (Figure 3). In the 
second method, polyclonal rabbit anti-HBsAg antibody 
was used to coat the wells. In this assay, either phage 
particles displaying HBsAg or wild-type phages were 
used as the primary antibody, and a mouse anti-M13/ 
HRP conjugate was used as the secondary antibody. The 
binding signal for HBsAg-displaying phages was 7.7 
times higher than the binding signal for the wild-type 
phages (Figure 3). 
3.3. ELISA of Mice Sera 
Immunizations of 8-week-old male BALB/cJ mice were 
performed by intradermal injections of the phage nano-
particles at different concentrations (1010, 1011 or 1012 
phage particles). The immunizations used either HBsAg- 
displaying recombinant phage nanoparticles, wild-type 
phage nanoparticles or PBS. 
Three injections were performed at three-week inter-
vals, and mouse blood was collected prior to each inject- 
tion. For determining the immune response developed 
against HBsAg an ELISA test against anti-HBsAg anti-  
 
Figure 2. Schematic representation of phage ELISA methods 
for the detection of HBsAg displayed on M13 phage surfaces. 
First method: Phage particles with or without (wild-type phage) 
HBsAg display were used to coat ELISA plate wells. Poly-
clonal rabbit anti-HBsAg antibody (1/200) was used as a pri-
mary antibody, and goat anti-rabbit alkaline phosphatase con-
jugate was used as a secondary antibody. The absorbance was 
measured at 405 nm. Second method: ELISA plate wells were 
coated with rabbit anti-HBsAg polyclonal antibody. Phage par- 
ticles displaying HBsAg or wild-type phage were then added 
to each well. Mouse anti-M13 horseradish peroxidase conju-
gate was used as a secondary antibody. The absorbance was 
measured at 410 nm. 
 
 
Figure 3. The binding profile of HBsAg displayed on phages 
with anti-HBsAg polyclonal antibodies. Wavelengths of 405 
nm and 410 nm were used to measure the optical absorbance 
for the first and second ELISA methods, respectively. 
 
bodies in mice sera was conducted. The injections gave 
no signal for mice immunized with 1010 and 1011 phage 
particles (data not shown). However, a three-fold in-
crease in absorbance was observed in the sera of mice 
immunized with 1012 recombinant phage nanoparticles 
displaying HBsAg. A mixed model ANOVA with Tukey 
post hoc test was conducted to assess the immune re-
sponse difference between different treatment groups 
(phage particles displaying HBsAg, phage particles with- 
out HBsAg and PBS) across different injection periods 
(Before injection, first injection, second injection and 
third injection). There was a statistically significant inte-
raction between the treatment groups and the injections 
on the immune response, F(6,18) = 80.208, p < 0.0005, 
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partial eta squared = 0.964. Then univariate General Li-
near Model with Tukey post hoc analysis were conducted 
to determine the differences of immune responses be-
tween groups at each level of injection periods. There 
immune response was statistically lower in the PBS 
group (M = 0.39, SE = 0.017, p < 0.0005) and the phage 
particles without HBsAg group (M = 0.38, SE = 0.017, p 
< 0.0005) compared to the phage particles dispaying 
HBsAg group (Figure 4). 
4. DISCUSSION 
The manufacture of proteins is the critical component in 
diverse fields such as agriculture, biotechnology and 
health care. Many different processes and methods have 
been developed to produce and purify proteins of eco-
nomic importance, although these protocols can be diffi-
cult, time consuming and expensive [20]. Natural pro-
teins can be purified from their host cells, but the result-
ing pure protein yields can be very low. Therefore, re-
combinant protein technology has revolutionized the tar- 
get protein expression protocols.  
HBsAg is a key antigen used either for HBV infection 
diagnosis or HBV vaccines. HBsAg has been produced 
in many different mammalian, microbial and plant cell 
systems [21-23]. Although large amounts of HBsAg are 
produced by these systems, the procedures for purifying 
HBsAg remain costly and time consuming.  
Phage display technology is a powerful approach for 
the expression of proteins, peptides, enzymes and anti-
bodies on phage surfaces [9,24,25]. However, phage dis-
play allows for the expression of the target protein only 
as a fusion with the cell surface or coat proteins. Even if 
proteins expressed on the phage surface are not “pure”, 
they are easy to produce and purify using a simple PEG 
precipitation step followed by centrifugation. These 
properties make them suitable for immunization purpos-
es because phages are antigenic and immunogenic and 
are capable of inducing antigen-specific antibodies by 
recruiting helper T cells without the requirement of an 
adjuvant [26,27]. As a result, phages have been used to 
elicit immune responses in animal models [28,29] with 
the intent of using phage nanoparticles in vaccine devel-
opment. Several studies on HIV-1 [30], hepatitis C virus 
(HCV) [31], Alzheimer’s disease [32] and cancer [17] 
have demonstrated the potential use of phage-displayed 
antigens in the development of vaccines in mice and rab-
bits. The first phage display-based vaccine system for 
large animals was recently developed against Taenia so-
lium pig cysticercosis [33].  
In most phage display immunization studies, antigenic 
peptides were displayed on the PVIII major coat proteins 
[34,35]. This method is used mainly because of the high 
copy number of PVIII coat proteins (~2500 copies) com- 
pared to the PIII minor coat protein number, which varies 
 
Figure 4. ELISA results for mice immunized with 1012 phage 
nanoparticles before the first injection and after each injections. 
ELISA plate wells were coated with 200 ng of HBsAg, and the 
wells were then treated with 1/50 diluted mouse serum. Anti- 
mouse HRP conjugate was used as the detection antibody. The 
absorbance was measured at 410 nm. 
 
from three to five copies [36]. Prior to this present study, 
the HBsAg immunogenic epitope (HBsAg111-156) or 
the hepatitis virus B pre-S1 region (47 and 49 amino ac- 
ids regions of PRES1) has been displayed on T7 bacteri-
ophage nanoparticles [6,15] and used for immunization 
and vaccination purposes. In these studies, T7 bacterio-
phage nanoparticles were used because the displayed 
peptide size is too large to use on the PVIII coat proteins 
of filamentous phages. Another reason is the high copy 
number of 10B capsid proteins (415 copies). The expres-
sion of a high peptide antigen copy number is an impor-
tant criterion for vaccine application because a substan-
tial immune response can be obtained, although this re-
sponse is generated against a single epitope [37]. Certain 
epitopes are known to be common to different antigens, 
and thus, a single epitope vaccination can cause unex-
pected immune responses against antigens with the same 
epitope. Therefore, immunizations containing the entire 
antigen generate a more specific response against the 
target [38,39]. Recently, a full-length HBV core antigen 
(HBcAg) was displayed on the phage surface as a pIII 
fusion [40]. In addition, Ozdemir-Bahadir and colleagues 
successfully obtained anti-HBcAg monoclonal antibo-
dies from BALB/c mice immunized with HBcAg-dis- 
playing phages.  
The goal of this present study was to express the 
full-length small HBsAg on the surface of an M13 fila-
mentous phage as a PIII fusion protein. The gene coding 
the full-length HBsAg was cloned into a pCANTAB5E 
phagemid vector for this purpose. After the gene inser-
tion was confirmed by DNA sequence analysis, infective 
phages displaying HBsAg were obtained. Small HBsAg 
expression was confirmed by two different ELISA me-
thods, as illustrated in Figure 2. In both methods, a 
binding signal was expected if HBsAg was displayed on 
phage surfaces, and if no HBsAg was displayed (wild- 
type phages), then no signal was expected. The ELISA 
results from both methods clearly showed a specific 
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binding between phages displaying HBsAg and polyc-
lonal anti-HBsAg antibodies. In contrast, no binding for 
the wild-type phages to the polyclonal anti-HBsAg anti-
bodies was detected, as expected. Therefore, the expres-
sion of HBsAg on the phage surfaces was confirmed. 
The HBsAg-displaying phage nanoparticles were then 
used for immunization assays. The results showed that 
injections of 1010 and 1011 phage nanoparticles were not 
sufficient to generate an immune response against HBsAg 
but were sufficient for generating an immune response 
against an M13 phage (data not shown). A significant (p 
< 0.05) anti-HBsAg immune response was observed in 
mice immunized with 1012 recombinant phage nanopar-
ticles after the third immunization. Therefore, our results 
demonstrated that at least 1012 recombinant phage nano-
particles are necessary to generate an immune response 
against HBsAg. 
The present results support the concept that M13 
phages are good antigen carriers built upon the inexpen-
sive and easy phage display method to express HBsAg 
for immunization. Furtherour results demonstrate that full- 
length HBV small surface antigen displayed on M13 phage 
minor pIII coat proteins can activate an anti-HBsAg im-
mune response in BALB/cJ mice, even at a very low pIII 
copy number. 
5. CONCLUSION 
To date, phage nanoparticles have been used as potential 
vaccine delivery vehicles, and several immunization stu-
dies against HBsAg have been conducted using phage 
display. However, these studies used short regions of 
antigens displayed on M13 PVIII major coat proteins. 
This present study describes the first successful expres-
sion of the small HBsAg on an M13 filamentous phage 
surface as a pIII fusion protein and the use of these re-
combinant phage nanoparticles as an immunization agent 
without the need of any additional adjuvant.  
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